Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

The availability of a rule-in-rule-out test for Alzheimer’s disease in primary care settings is likely to drive efficiencies throughout the care continuum.

Eli Lilly said it received marketing authorization from the European Commission for Kisunla, a treatment for early symptomatic Alzheimer's disease. Kisunla showed in a phase 3 trial that it can ...

Novo Nordisk’s ambitious trial into whether its blockbuster obesity drug, semaglutide, could treat Alzheimer’s disease has been described as a "lottery ticket" by a senior executive, highlighting its ...

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the ...

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

After decades of unsuccessful research, two new drugs and a pioneering blood test have recently given Alzheimer's patients hope of fighting back against the debilitating disease - but questions remain ...

A second blood test has been been approved by the US Food and Drug Administration to assist in diagnosing Alzheimer’s disease ...

Eli Lilly continues to establish its dominance in the growing market for GLP-1 therapies. The company's oral candidate for diabetes treatment and weight loss looks very promising. Even after soaring ...

The US pharmaceutical company Eli Lilly has met with the Department of Enterprise to express concerns about planned changes to the patent law in Europe. The multinational, which employs 3,500 people ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...